Time limits apply in California. Find out if you still qualify.
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Verified against court and regulatory records · No upfront fees · Your information is never sold
Statute of limitations — California
California Code of Civil Procedure § 335.1 provides a 2-year statute of limitations for personal injury claims including pharmaceutical product liability. The discovery rule applies — the limitations period begins when the plaintiff discovers or reasonably should have discovered the injury and its connection to Tepezza. California does not have a statute of repose for product liability, allowing claims based on late-discovered hearing damage.
2 years from discovery of Tepezza-related hearing injury
Filing venue
Where to File in California
Federal Tepezza cases filed in California are transferred to the MDL in the Northern District of Illinois (MDL No. 3079). California state court claims may proceed independently in Los Angeles, San Francisco, or San Diego Superior Courts. California applies the Kelly/Frye standard for expert admissibility rather than the federal Daubert standard, which can affect causation testimony in state court proceedings. California's plaintiff-friendly discovery rule and lack of a product liability statute of repose make it a favorable venue for hearing damage claims.
California data
Exposure in California
California population — largest potential Tepezza patient pool of any state, with the highest concentration of endocrinology and ophthalmology treatment centers
39.5 million
Source: U.S. Census Bureau 2024
Approximate cost of a full Tepezza treatment course (8 infusions over 21 weeks), making it one of the most expensive drugs in the U.S.
$300,000
Source: Horizon Therapeutics prescribing information
Percentage of Tepezza patients who developed new otologic symptoms after an average of 3.8 infusions in a published study
81.5%
Source: PMC / National Library of Medicine
Keep reading